Selected IIR references (for abstracts, see Lists of IIR Publications):
Svenson et al. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993; 92:2533-2539.
Ros et al. Specific autoantibodies directed against interferon-a in pharmaceutically prepared human immunoglobulin preparations. J Interferon Res 1994;14:159-60.
Ross et al. High avidity IFN-neutralising antibodies in pharmaceutically prepared human IgG. J Clin Invest 1995; 95:1974-1978.
Bendtzen et al. Cytokine autoantibodies. In: Peter JB, Shoenfeld Y, editors. Autoantibodies. Amsterdam: Elsevier Science B.V.; 1996. p. 209-16. (Review).
Bendtzen et al. High-avidity autoantibodies to cytokines. Immunol Today 1998;19:209-11. (Review).
Bendtzen et al. Detection of autoantibodies to cytokines. Mol Biotechnol 2000;14:251-61. (Review).
Bendtzen et al. Natural and induced anti-cytokine antibodies. In: Ciliberto G, Savino R, editors. Cytokine inhibitors. New York: Marcel Dekker; 2000. p. 53-95. (Review).
Myhr et al. neutralising antibodies to interferon (IFN) a-2a and IFN b-1a or IFN b-1b in MS are not cross-reactive. Neurology 2000;55:1569-71.
Ross et al. Immunogenicity of interferon-b in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-12.
Sorensen et al. Therapy-induced antibodies against interferon-beta-1a and interferon-beta-1b in patients with multiple sclerosis. Danish Multiple Sclerosis Study Group. In: Kappos L, Johnson K, Kesselring J, Radü EW, editors. Multiple Sclerosis. Tissue destruction and repair - New immunomodulating therapies. Danish Multiple Sclerosis Study Group. London: Martin Dunitz; 2000. p. 323-6.
Stylianou et al. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clinical and Experimental Immunology 2000;119:479-85.
Ross et al. IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-a2a. J Interferon Cytokine Res 2002;22:421-6.
Bendtzen K. Problemer ved klinisk brug af rekombinante proteiner (Editorial). Ugeskr Laeger 2003;48:4625.
Bendtzen K. Immunogenicitet af biologiske lægemidler. Erfaringer med betainterferon, EPO og anti-TNF (Immunogenicity of biopharmaceuticals. Experience with interferon-beta, EPO and anti-TNF)(Review). Ugeskr Laeger 2003;48:4629-32.
Sorensen et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-91.
Bendtzen K. Anti-IFN BAb and NAb antibodies: A minireview. Neurology 2003;61, Suppl. 5:S6-S10 (Review).
Sorensen et al. Neutralising antibodies against interferon beta in multiple sclerosis. Lancet 2004;363:168-9 (letter).
Bendtzen K. Natural and therapy-induced antibodies to cytokines. Drug Discovery Today 2004;9:259.
